Rifabiz contains Rifaximin. Rifabiz uses:
Acute infectious diarrhoea including travelers diarrhoea, Diarrhoea predominant Irritable Bowel Syndrome (IBS-D), Hepatic Encephalopathy (H.E.)
|Therapeutic Class:||Miscellaneous Antibiotics|
|Manufacturer:||ALNICHE LIFE SCIENCES PVT LTD|
|Last Updated:||2020-11-21 18:15:00|
Rifabiz contains Rifaximin 200.0 Mg. Rifabiz doses
Acute Infectious Diarrhoea including Travelers’ Diarrhoea: 200 mg three times daily for 3 days.
Diarrhoea predominant Irritable Bowel Syndrome (IBS-D): 550 mg three times daily for 14 days.
Hepatic Encephalopathy (H.E.): 550 mg twice daily
Common side effects are nausea, vomiting, abdominal pain, flatulence, headache and dizziness.
Rifabiz is a non-aminoglycoside semi-synthetic antibacterial derived from rifamycin SV. It inhibits bacterial RNA synthesis by binding to the bacterial DNA-dependent RNA polymerase and has antibacterial activity against Escherichia coli (E. coli).
Pregnancy and lactation. Caution in severe hepatic impairment (Child-Pugh class C). Not effective against diarrhoea caused by pathogen other than E. coli ; or diarrhoea complicated by fever and/or blood in the stool. Prolonged use may result in Clotridum difficile-associated diarrhoea. Severe hepatic impairment (Child-pugh class C).
Although In vitro studies demonstrated the potential of Rifabiz to interact with cytochrome P450 (CYP3A4), a clinical drug-drug interaction study demonstrated that Rifabiz did not significantly affect the pharmacokinetics of midazolam. An additional clinical drug-drug interaction study showed no effect of Rifabiz on the presystemic metabolism of an oral contraceptive containing ethinyl estradiol and norgestimate. Therefore, clinical interactions with drugs metabolized by human cytochrome P450 isozymes are not expected.
Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Rifabiz should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus.
Use in Lactation: It is not known whether Rifabiz is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for adverse reactions in nursing infants from Rifabiz, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Rifabiz is contraindicated in patients with a hypersensitivity to Rifabiz, or any of the Rifamycin antimicrobial agents, or any of the components of this preparation.
Use in Children: The safety and effectiveness of Rifabiz 200 mg in pediatric patients with travelers’ diarrhoea less than 12 years of age have not established.The safety and effectiveness of Rifabiz 550 mg for hepatic encephalopathy have not been established in patients <18 years of age.
Use in geriatric patients: Clinical studies of Rifabiz tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects.
Use in Renal Insufficient Patients:The pharmacokinetics of Rifabiz in patients with impaired renal function has not been studied.
Use in Hepatic Insufficient Patients:No dosage adjustment with Rifabiz is necessary due to its limited systemic absorption. Nonetheless, caution should be exercised when Rifabiz is administered to patients with severe hepatic impairment.
No specific information is available on the treatment of over dosage with Rifabiz. In case of over dosage, discontinue Rifabiz, treat symptomatically and institute supportive measures as required.
Store at 20-25° C; excursions permitted to 15-30° C.
Rifabiz Tablet price in India 119